Previous 10 | Next 10 |
2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuite SM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call ...
AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the...
AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million live...
Aspira Women’s Health ( NASDAQ: AWH ) sees preliminary testing volume during the fourth quarter of 2022 of 5,643, an increase of 18 % compared to the fourth quarter of 2021 . The number of OvaSuite SM tests performed increased 23% to 21,424 tests during the year end...
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 Further reduced staff t...
Provides clinical validation for the use of OvaWatch SM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the peer-reviewed journal, Frontiers in Medicine AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- As...
Expanded Medicare coverage for multi-marker testing, including Ova1Plus ® and OvaWatch SM , through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American Medical Association Expanded Medicaid coverage adding another 5 sta...
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of OvaWatch SM , a new non-invasive blood-based test for the ...
Aspira Women's Health Inc. (AWH) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Robert Beechey - Chief Fin...
Aspira Women’s Health press release ( NASDAQ: AWH ): Q3 GAAP EPS of -$0.04. Revenue of $2.1M (+23.5% Y/Y). Q3 product volume up 29% to 5,524 units . Q3 gross profit margin for Ova1Plus was relatively flat at 57%. As of Sept 30, 2022, Aspira had...
News, Short Squeeze, Breakout and More Instantly...
Aspira Women's Health Inc. Company Name:
AWH Stock Symbol:
NASDAQ Market:
Aspira Women's Health Inc. Website:
Preliminary OvaWatch ® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuite SM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Heal...
AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that i...
AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has...